2023 Announcements

CLINUVEL
Posted by CLINUVEL
January 31, 2023

Appendix 4C & Activity Report

Melbourne, Australia, 31 January 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
January 27, 2023

Technical Note: Developing a melanocortin pipeline

CLINUVEL today announced an update on its commercial development of the analogue...

Read More
CLINUVEL
Posted by CLINUVEL
January 23, 2023

NEURACTHEL® manufacturing processes advance

CLINUVEL today announced an update on its commercial development of the analogue...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2023

Media release: CLINUVEL Trial Results Show Drug Reduces DNA Damage

Results from a clinical trial in a genetic DNA repair disorder show...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2023

Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum - Technical Note

Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2023

Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum

Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
January 12, 2023

News Kommuniqué 1

Happy New Year to all our stakeholders for 2023, a year in...

Read More
CLINUVEL
Posted by CLINUVEL
January 10, 2023

News Communiqué I

On behalf of the CLINUVEL team and Board, I wish all readers...

Read More